Latest News & Features
Refine Search
Americas
A recent study revealed that biotechnology companies or universities discovered 42 percent of all innovative drugs approved by the US Food and Drug Administration (FDA) between 1998 and 2007. 1 May 2011
Americas
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs. 1 May 2011
Generics
Natural products have been used to relieve a variety of diseases and conditions for millennia. 1 May 2011
Americas
US patent reform looks like it may finally be coming. John Pegram and Mark Ellinger explain the proposed changes. 1 May 2011
Americas
As biotechnology patents continue to grow in importance, uncertainty remains on both sides of the Atlantic as to exactly what is patentable. Simon O’Brien and David Gass take a look. 1 May 2011
Americas
The Canadian Federal Court of Appeal recently considered whether ‘invalid selection’ can be an independent ground for invalidating selection patents. Katie Wang looks at the implications. 1 May 2011
Biotechnology
A growing number of biotechnology inventions relate to peptides, oligonucleotides and other small molecules that could be used in therapeutic applications. Caroline Pallard explains the challenges of patenting such inventions. 1 May 2010
Americas
A recent US district court ruling could significantly affect companies that patent genes and threaten the health of an entire industry. LSIPR investigates. 1 May 2010
Biotechnology
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains. 1 May 2010
Europe
Following the implementation of EU Directive 2004/48/EC on the enforcement of IP rights under French patent law in 2007 and the publication of the corresponding implementing rules in 2008, the criteria adopted by the French courts to grant preliminary injunctions have also changed. 1 May 2010